论文部分内容阅读
目的 观察软肝缩脾丸对纤维化大鼠肝脏基质金属蛋白酶组织抑制因子 -1、2 (TIMP -1、TIMP -2 )及Ⅰ、Ⅲ型胶原mRNA及蛋白表达的影响 ,从胶原降解的角度探索中药抗肝纤维化的可能机理。方法 制备大鼠肝纤维化模型 ,并给予软肝缩脾丸治疗 ;用原位杂交和免疫组化的方法分别测定TIMP -1、TIMP -2及Ⅰ、Ⅲ型胶原的mRNA和蛋白表达。结果 CCl4模型组TIMP -1、TIMP -2 ,Ⅰ、Ⅲ型胶原mRNA及蛋白水平明显高于治疗组。正常组大鼠肝组织无一例阳性。结论 TIMP -1、TIMP -2与肝纤维化形成密切相关 ,软肝缩脾丸可以抑制纤维化肝脏TIMP -1、TIMP -2的表达 ,从而增强间质胶原酶的活性 ,促进Ⅰ、Ⅲ型胶原的降解 ,产生抗肝纤维化作用。
Objective To observe the effect of Ruangan Shupi Pill on the mRNA and protein expression of liver tissue inhibitors of matrix metalloproteinase-1 (TIMP-1, TIMP-2) and type I and type III collagen in rats with fibrosis, from the perspective of collagen degradation. Exploring the possible mechanism of anti-hepatofibrosis in traditional Chinese medicine. Methods Rat hepatic fibrosis model was prepared and treated with Ruangan Shupi Pill. The mRNA and protein expressions of TIMP-1, TIMP-2, collagen type I and III were measured by in situ hybridization and immunohistochemistry, respectively. Results The mRNA and protein levels of TIMP-1, TIMP-2, type I and type III collagen were significantly higher in the CCl4 model group than in the treatment group. There was no positive liver tissue in normal rats. Conclusions TIMP-1 and TIMP-2 are closely related to the formation of hepatic fibrosis. Ruangan Shupi Pill can inhibit the expression of TIMP-1 and TIMP-2 in the fibrotic liver, thereby enhancing the activity of interstitial collagenase and promoting Type I and Type III. Degradation of collagen produces anti-hepatic fibrosis.